/PRNewswire/ Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today its decision not to continue the.
/PRNewswire/ Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing.
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency
News provided by
Share this article
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)
( Calliditas ) today announced that the company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).
The submission is based on positive data from Part A of the NefIgArd pivotal Phase 3 study, a randomized, double-blind, placebo-controlled, international multicenter study designed to evaluate the efficacy and safety of Nefecon compared to placebo in 200 adult patients with IgAN. The study achieved its primary endpoint of proteinuria reduction compared to placebo, and also showed a renal protective effect by way of stabilization of eGFR at 9 months.
/PRNewswire/ NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare disorders.
/PRNewswire/ MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first.